Scalp psoriasis can cause crusty patches or scales on the surface of the head. Find details about medicated shampoos, ...

Medically reviewed by Susan Bard, MD Psoriasis and dandruff can both trigger itching and flaky scalp skin. Psoriasis is a ...

Optimizing use of topical agents begins with defining "mild or moderate." Clinical trials in psoriasis employ objective ...

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic ...

Discover a study where patients initially receiving placebo experienced notable improvement after switching to tildrakizumab.

Data demonstrated favorable safety and local tolerability of ZORYVE® (roflumilast) cream 0.15% in adults and children with atopic dermatitis (AD) ...

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study Topline results from ...

This phase 3b clinical trial focused on safety and efficacy of the anti-IL-23 inhibitor in scalp psoriasis. Patients taking tildrakizumab had scalp improvement by 16 weeks, which continued through ...

Five-year data from Phase III trials demonstrated that 67.7% of patients moderate-to-severe plaque psoriasis treated with UCB ...

Despite these limitations, the researchers believe the study confirmed the efficacy and safety of bimekizumab and brodalumab ...

Johnson & Johnson (NYSE: JNJ) today announced new icotrokinra (JNJ-2113) data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis ...